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Abstract
In this study, 22 new betulinic acid (BA) derivatives were synthesized and tested for their
inhibition of the chymotrypsin-like activity of 20S proteasome. From the SAR study, we
concluded that the C-3 and C-30 positions are the pharmacophores for increasing the proteasome
inhibition effects, and larger lipophilic or aromatic side chains are favored at these positions.
Among the BA derivatives tested, compounds 13, 20, and 21 showed the best proteasome
inhibition activity with IC50 values of 1.42, 1.56, and 1.80 µM, respectively, which are three- to
four-fold more potent than the proteasome inhibition controls LLM-F and lactacystin.
Betulinic acid (BA, 3β-hydroxy-lup-20(29)-en-28-oic acid, 1) is a pentacyclic triterpene
present in many plant species, e.g., Triphyophyllum peltatum, Ancistrocladus heyneanus,
Ziziphi fructus, Diospyros leucomelas, Tetracera boliviana and Syzygium formosanum,1–3
and can be obtained in quantity from the bark of the London plane tree, Platanus
acerifolia.4–6 BA (1) exhibits diverse biological activities including anti-retroviral, anti-
bacterial, anti-malarial, anti-inflammatory, anti-cancer, anti-oxidant, and anthelmintic
properties. Our previous research on 1 resulted in the discovery of bevirimat [DSB, 3-O-(3’,
3’-dimethylsuccinyl)-betulinic acid, 2] (Figure 1),7 which exhibits remarkable anti-HIV-1
activity with a mean EC50 value of <10 nM against primary and drug-resistant HIV-1
isolates,7, 8 representing a unique first in a class of anti-HIV compounds termed maturation
inhibitors (MIs).8, 9 Bevirimat has recently succeeded in Phase IIb clinical trials.6, 10–12 In
the further evaluation of 2, we discovered that HIV-1 virions produced in the presence of 2
contained higher amounts of the cellular protein APOBEC3G, which is usually degraded by
cellular proteasomes. We then postulated that the elevated APOBEC3G level in these viral
infected cells may be due to the inhibition of proteasomes by 2.
Proteasomes are responsible for more than 80% of intracellular protein degradation.13 The
most common form of the proteasome is known as 26S proteasome, which contains one 20S
core particle structure and two 19S regulatory caps. All 20S particles consist of four stacked
heptameric ring structures that are themselves composed of two different types of subunits,
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α and β. Alpha subunits are structural in nature, whereas β subunits are predominantly
catalytic. The β subunits of proteasomes have three major proteolytic activities:
chymotrypsin-like (β5), trypsin-like (β2), and caspase-like (β1). These proteolytic activities
enable the proteasome to cleave proteins into small peptides. Proteasomes are involved in
many essential cellular functions, such as cell cycle regulation, cell differentiation, signal
transduction pathways, antigen processing for appropriate immune responses, stress
signaling, inflammatory responses, and apoptosis. Targeting the proteasome-ubiquitin
pathway has thus been considered a novel strategy for the treatment of various disorders
such as neurodegenerative diseases, cancers, and inflammatory diseases.14, 15
In our initial screening, we found that 2 inhibited the chymotrypsin-like activity of 20S
proteasome with an IC50 value of 9.2 µM, but it did not inhibit the caspase-like activity, and
had a very weak inhibitory effect (IC50: 26.29 µM) on the trypsin-like activity.16 These
results are favorable because normal cells may suffer fewer consequences from treatment
with 2, as two of the main proteolytic activities of proteasomes are retained. Indeed, the
anticancer drug bortezomib (PS341), the first successful proteasome inhibitor for the
treatment of multiple myeloma, also showed differential inhibition of the three catalytic
activities of proteasomes, which is believed to be critical for its clinical benefit in disease
treatment.14, 17, 18 In addition, compound 2 did not inhibit the cellular proteases cathepsin B
(cysteine protease) and DPPIV (DPP4, CD26, serine protease) in our screening.16
Consequently, it may have reduced side effects compared with other proteasome inhibitors
such as peptide aldehydes and peptide boronates, which also inhibit these cellular proteases.
Therefore, to better establish a structure-activity relationship (SAR) of the proteasome
regulatory activity of BA derivatives, diverse substituted BA analogs were designed. This
paper reports herein the synthesis and proteasome inhibitory activity of these BA
derivatives.
Because 2 is a C-3 modified BA derivative, we first synthesized eleven 3-O-acyl-BA
analogs (3–13) to investigate the impacts of different C-3 modifications on the proteasome
inhibitory activity of BA derivatives. As shown in Scheme 1, 3,4,5-trimethoxybenzoyl
chloride was reacted with 1 in the presence of Et3N in CH2Cl2 at room temperature to yield
compound 3. Diverse carboxylic acids were first treated with EDCI and DMAP in CH2Cl2
for 1 h, before compound 1 and Et3N were added into the system. The mixtures were stirred
at room temperature to yield compounds 4–10 and 13. 1,2,3,6-Tetrahydrophthalic and
diglycolic anhydrides were refluxed with 1 in the presence of DMAP in pyridine to provide
compounds 11 and 12, respectively. To investigate the impact of 28- and 30-subsitutions on
BA’s proteasome inhibitory effects, nine 28,30-disubstituted BA analogs (14–22) were
synthesized by the method reported previously (Scheme 2)19 and were also tested against
20S proteasome. Briefly, BA was first protected with acetic anhydride to yield 25, which
was treated with oxalyl chloride and then reacted with leucine methyl ester to furnish 26.
Allylic bromination of 26 was carried out using NBS in dilute acetonitrile to provide 27.
Saponification of 27 yielded 14. Meanwhile, nucleophilic displacement of the bromide of 27
was conducted by treating varied nucleophilic compounds with NaH, followed by their
reaction with 27 in a microwave apparatus at 120 °C. Saponification of the resulting
mixtures in MeOH-H2O converted the intermediate esters to carboxylic acids to yield the
target compounds 15–22. Two compounds with only a C-28 side chain, LH15bh (23) and
IC9564 (24) (Figure 1),20, 21 were also tested for their proteasome inhibition activity to
investigate the influence of C-28 mono-substitution.
Table 1 lists the results for inhibition of the chymotrypsin-like activity of 20S proteasome
shown by BA derivatives 3–2422 together with compound 2. Known proteasome inhibitors
Ac-Leu-Leu-Met-CHO (LLM-F) and lactacystin were also included in the in vitro 20S
proteasome assay23 as controls. From the results with compounds 2–13, we can conclude
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that addition of a C-3 ester group to 1 can confer proteasome inhibition activity and the
identity of the ester group can influence the potency. Comparing the activity of 3–10, we
found that compound 6 with an unsubstituted benzoate ester side chain and compound 5
with 2′,4′,5′-trimethoxy substituted benzoate ester side chain at the C-3 position showed
moderate inhibition activity (IC50: 11.06 and 10.91 µM, respectively) on the chymotrypsin-
like activity of 20S proteasome. Compounds 3, 4, and 7 without ortho-methoxy substitution
on benzoate ester side chain abolished or greatly decreased the proteasome inhibition
activity. In a comparison of three compounds with different brominated benzoate side
chains, bromide on the 2′- or 3′-position (8 and 10) was advantageous (IC50: 7.99 and 7.05
µM, respectively), while bromide on the 4′-position (9) was detrimental. Interestingly, while
compound 12, with a polar oxygen atom in the middle of a diglycolic ester side chain was
inactive, compounds with both a cyclohexene ring (11) and a phenyl ring (13), located
centrally within a dicarboxylic side chain were significantly active. Compound 11, with a
1,2,3,6-tetrahydrophthlate ester side chain, exhibited increased proteasome inhibition
activity with an IC50 value of 2.96 µM. Elongation of the C-3 side chain to 3′-
acetylphenylacetate (13) further increased the proteasome inhibition activity to an IC50
value of 1.42 µM, which is six-fold better than 2 and four-fold better than LLM-F and
lactacystin. Among the synthesized 3-O-acyl BA analogs, compound 13 showed the best
activity, suggesting that an aromatic lipophilic ester side chain with a carboxylic acid
terminus at the C-3 position can significantly increase the proteasome inhibition activity of
BA derivatives.
With respect to the effects of 28- and 30-substitutions on the proteasome activity, we found
that all nine 28,30-disubstituted BA analogs (14–22) showed inhibitory activity towards the
chymotrypsin-like activity of 20S proteasome. However, the 28-substituted BA derivatives
23 and 24 did not inhibit the 20S proteasome to any degree. We therefore concluded that the
proteasome inhibition activity of the 28,30-disubstituted BA compounds comes mainly from
the contribution of the C-30 substituents. Within the C-30 side chains, larger ether
substituents (16–22) were favored compared with bromide (14) or a smaller ethoxy group
(15). Among 16–22, the rank order of potency based on the C-30 ether substituent was 4′-
bromophenethoxy (20) = 4′-chlorophenethoxy (21) > 4′-fluorophenethoxy (19) =
phenethoxy (17) > propoxy (16) = 4′-methyoxyphenethoxy (18) = 2′-morpholinoethoxy
(22). Overall, compound 15 with an ethoxy substituent showed the lowest activity among
the 28,30-disubstituted BAs with an IC50 value of 13.21 µM, while compounds 20 and 21
with 4′-bromophenethoxy and 4′-chlorophenethoxy substituents, respectively, showed the
highest activity with IC50 values of 1.56 and 1.80 µM, respectively, three-fold better than
LLM-F and lactacystin. Thus, longer C-30 side chains with aromatic substitutions were
favored for the proteasome inhibition activity.
In summary, this study showed that substituted BA analogs can be proteasome inhibitors,
and the C-3 and C-30 positions of BA are the pharmacophores for improving the proteasome
inhibition activity. Within the C-3 and C-30 substitutions, larger side chains with lipophilic
or aromatic side chains are favored for increased inhibition of the chymotrypsin-like activity
of 20S proteasome. C-3 and C-30 modified BA compounds showed low toxicity in our
previous anti-AIDS studies, and bevirimat (2), a C-3 substituted BA, has already succeeded
in phase IIb clinical trials. Therefore, development of C-3 and/or C-30 modified BA
derivatives as proteasome inhibitors might be able to provide new therapeutic agents for
treating cancers and inflammatory diseases.
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Crude samples were dissolved in the appropriate solvent before being injected automatically via
solid loading. Spectroscopic data for target compounds are shown as follows. Compound 3: 1H
NMR (400 MHz, CDCl3): δ 7.29, 7.27 (1H each, s, Ar-H), 4.76, 4.64 (1H each, s, H-29), 4.60
(1H, m, H-3), 3.94 (3H, s, Ar-OCH3), 3.91 (6H, s, 2 × Ar-OCH3), 3.06 (1H, m, H-19), 1.71 (3H, s,
H-30), 0.97, 0.90, 0.83, 0.76, 0.70 (3H each, s, 5 × CH3), MS m/z 649.50 (M− - 1); Compound
4: 1H NMR (400 MHz, CDCl3): δ 7.64 (1H, d, J = 8.0 Hz, Ar-H-6′), 7.45 (1H, s, Ar-H-2′), 6.84
(1H, d, J = 8.0 Hz, Ar-H-5’), 6.03 (2H, s, -OCH2O-), 4.73, 4.60 (1H each, s, H-29), 4.65 (1H, m,
H-3), 3.10 (1H, m, H-19), 1.70 (3H, s, H-30), 0.99, 0.97, 0.96, 0.90, 0.89 (3H each, s, 5 × CH3),
MS m/z 603.40 (M− - 1); Compound 5: 1H NMR (400 MHz, CDCl3): δ 7.44 (1H, s, Ar-H-6′), 6.52
(1H, s, Ar-H-3′), 4.75, 4.62 (1H each, s, H-29), 4.69 (1H, dd, J = 8.0, 4.0 Hz, H-3), 3.93, 3.88,
3.86 (3H each, s, 3 × Ar-OCH3), 3.01 (1H, m, H-19), 1.70 (3H, s, H-30), 1.00, 0.97, 0.96, 0.95,
0.89 (3H each, s, 5 × CH3), MS m/z 649.70 (M− - 1); Compound 6: 1H NMR (400 MHz, CDCl3):
δ 8.04 (2H, d, J = 8.0 Hz, Ar-H-2′, 6′), 7.55 (1H, m, Ar-H-4′), 7.45 (1H, m, Ar-H-3′, 5′), 4.75, 4.62
(1H each, s, H-29), 4.71 (1H, m, H-3), 3.02 (1H, m, H-19), 1.71 (3H, s, H-30), 1.00, 1.00, 0.96,
0.93, 0.91 (3H each, s, 5 × CH3), MS m/z 559.45 (M− - 1); Compound 7: 1H NMR (400 MHz,
CDCl3): δ 7.68 (1H, d, J = 4.0 Hz, Ar-H-6′), 7.56 (1H, s, Ar-H-2′), 6.88 (1H, d, J = 4.0 Hz, Ar-
H-5′), 4.75, 4.62 (1H each, s, H-29), 4.69 (1H, m, H-3), 3.96, 3.93 (3H each, s, 2 × Ar-OCH3),
3.02 (1H, m, H-19), 1.71 (3H, s, H-30), 1.00, 0.99, 0.96, 0.92, 0.90 (3H each, s, 5 × CH3), MS m/z
619.45 (M− - 1); Compound 8: 1H NMR (400 MHz, CDCl3): δ 7.75 (1H, d, J = 8.0 Hz, Ar-H-6′),
7.64 (1H, d, J = 8.0 Hz, Ar-H-3′), 7.37-7.28 (2H, m, Ar-H-4′, 5′), 4.78 (1H, m, H-3), 4.75, 4.62
(1H each, s, H-29), 3.01 (1H, m, H-19), 1.71 (3H, s, H-30), 1.00, 0.97, 0.95, 0.94, 0.89 (3H each,
s, 5 × CH3), MS m/z 639.40 (M+ + 1); Compound 9: 1H NMR (400 MHz, CDCl3): δ 7.89 (2H, d,
J = 8.0 Hz, Ar-H-2′, 6′), 7.59 (2H, d, J = 8.0 Hz, Ar-H-3′, 5′), 4.73, 4.60 (1H each, s, H-29), 4.70
(1H, m, H-3), 3.02 (1H, m, H-19), 1.70 (3H, s, H-30), 1.00, 0.99, 0.97, 0.91, 0.90 (3H each, s, 5 ×
CH3), MS m/z 637.65 (M− - 1); Compound 10: 1H NMR (400 MHz, CDCl3): δ 8.15 (1H, s, Ar-
H-2′), 7.95 (1H, d, J = 8.0 Hz, Ar-H-6’), 7.67 (1H, d, J = 8.0 Hz, Ar-H-4′), 7.31 (1H, m, Ar-H-5′),
4.75, 4.62 (1H each, s, H-29), 4.71 (1H, m, H-3), 3.01 (1H, m, H-19), 1.71 (3H, s, H-30), 1.00,
0.99, 0.96, 0.92, 0.91 (3H each, s, 5 × CH3), MS m/z 637.50 (M− - 1); Compound 11: 1H NMR
(300 MHz, CDCl3): δ 5.70 (2H, m, H-5′, 6′), 4.72, 4.60 (1H each, s, H-29), 4.48 (1H, m, H-3),
3.02 (1H, m, H-19), 2.83, 2.72 (1H each, m, H-2′, 3′), 2.32-2.27 (4H, m, 2 × CH2, H-4′, 7′), 1.68
(3H, s, H-30), 1.01, 0.97 (3H each, s, 2 × CH3), 0.89, 0.83, 0.81 (3H each, s, 3 × CH3), MS m/z
607.40 (M− - 1); Compound 12: 1H NMR (300 MHz, CDCl3): δ 4.72, 4.60 (1H each, s, H-29),
4.46 (1H, m, H-3), 4.23, 4.21 (2H each, s, H-2′, 4′), 3.01 (1H, m, H-19), 1.71 (3H, s, H-30), 1.00,
0.98, 0. 79, 0.88, 0.87 (3H each, s, 5 × CH3), MS m/z 571.60 (M− - 1); Compound 13: 1H NMR
(400 MHz, CDCl3): δ 7.82 (1H, s, Ar-H-2′), 7.57-7.50 (2H, m, Ar-H-4′, 6′), 7.30 (1H, m, Ar-H-5′),
4.72, 4.60 (1H each, s, H-29), 4.40 (1H, m, H-3), 3.63, 3.60 (2H each, s, 2 × Ar-CH2-CO-), 2.98
(1H, m, H-19), 1.68 (3H, s, H-30), 0.95, 0.90, 0.82, 0.72, 0.68 (3H each, s, 5 × CH3), MS m/z
631.78 (M− - 1); Compound 14: 1H NMR (300 MHz, CDCl3): δ 5.86 (1H, d, J = 8.0 Hz, -
CONH-), 5.11, 5.02 (1H each, s, H-29), 4.65 (1H, m, -NHCH-), 3.90 (2H, s, H2-30), 3.17 (1H, dd,
J = 9.7, 5.4 Hz, H-3), 3.10-3.03 (1H, m, H-19), 1.00 (6H, s, leucine moiety -(CH3)2), 0.96 (6H, s,
2 × CH3), 0.83, 0.80, 0.79 (3H each, s, 3 × CH3), MS m/z 646.41, 648.39 (M− - 1); Compound
15: 1H NMR (300 MHz, CDCl3): δ 5.88 (1H, d, J = 8.0 Hz, -CONH-), 4.93, 4.92 (2H, br s, H-29),
4.63-4.58 (1H, m, -NHCH-), 3.90 (2H, s, H2-30), 3.47 (2H, m, 30-OCH2CH3), 3.18 (1H, dd, J =
11.1, 5.4 Hz, H-3), 2.99 (1H, m, H-19), 2.50-2.32 (1H, m, H-13), 1.00 (9H, br s, 30-OCH2CH3,
leucine moiety -(CH3)2), 0.96 (6H, s, 2 × CH3), 0.89, 0.86, 0.85 (3H each, s, 3 × CH3), MS m/z
612.40 (M− - 1); Compound 16: 1H NMR (300 MHz, CDCl3): δ 6.13 (1H, br s, -CONH-), 4.91,
4.90 (2H, br s, H-29), 4.52 (1H, m, -NHCH-), 3.90 (2H, s, H2-30), 3.36 (2H, t, J = 6.9 Hz, 30-
OCH2CH2CH3), 3.18 (1H, dd, J = 11.1, 5.4 Hz, H-3), 2.99 (1H, m, H-19), 0.96, 0.94, 0.92, 0.89
(15H, m, 30-O(CH2)2CH3, leucine moiety -(CH3)2, CH3-23, 24), 0.82, 0.81, 0.79 (3H each, s, 3 ×
CH3), MS m/z 626.50 (M− - 1); Compound 17: 1H NMR (300 MHz, CDCl3): δ 7.68-7.62 (2H, m,
Ar-H-3′), 7.28-7.20 (3H, m, Ar-H-2′, 4′), 5.97 (1H, br s, -CONH-), 4.91, 4.90 (2H, br s, H-29),
4.44 (1H, m, -NHCH-), 3.93 (2H, s, H2-30), 3.64 (2H, t, J = 7.2 Hz, 30-OCH2CH2Ph), 3.17 (1H,
dd, J = 11.1, 5.4 Hz, H-3), 2.91 (1H, m, H-19), 2.57 (2H, m, 30-OCH2CH2Ph), 0.95 (12H, s,
leucine moiety -(CH3)2, CH3-23, 24), 0.89, 0.78, 0.74 (3H each, s, 3 × CH3), MS m/z 688.41 (M−
- 1); Compound 18: 1H NMR (300 MHz, CDCl3): δ 7.27, 7.16-7.13, 6.85-6.82 (4H, m, Ar-H-2′,
3′), 5.97 (1H, br s, -CONH-), 4.91, 4.89 (H each, br s, H-29), 4.48 (1H, m, -NHCH-), 3.93 (2H, s,
H2-30), 3.79 (3H, s, Ar-OCH3), 3.60 (2H, t, J = 7.2 Hz, 30-OCH2CH2Ph(p-OCH3)), 3.17 (1H, dd,
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J = 11.1, 5.4 Hz, H-3), 2.85 (1H, t, J = 7.5 Hz, H-19), 2.39 (3H, m, 30-OCH2CH2Ph(p-OCH3),
H-13), 0.95, 0.93, 0.90 (15H, s, leucine moiety -(CH3)2, 3 × CH3), 0.79, 0.75 (3H each, s, 2 ×
CH3), MS m/z 718.50 (M− - 1); Compound 19: 1H NMR (300 MHz, CDCl3): δ 7.16-6.80 (4H, m,
Ar-H-2′, 3′), 5.96 (1H, br s, -CONH-), 4.90, 4.89 (2H, br s, H-29), 4.48 (1H, m, -NHCH-), 3.92
(2H, s, H2-30), 3.61 (2H, t, J = 7.2 Hz, 30-OCH2CH2Ph(p-F)), 3.17 (1H, m, H-3), 2.87 (1H, t, J =
7.5 Hz, H-19), 2.36-2.10 (3H, m, 30-OCH2CH2Ph(p-F), H-13), 0.95, 0.88 (15H, s, leucine moiety
-(CH3)2, 3 × CH3), 0.75, 0.73 (3H each, s, 2 × CH3), MS m/z 706.40 (M− - 1); Compound 20: 1H
NMR (300 MHz, CDCl3): δ 7.56-7.28 (4H, m, Ar-H-2′, 3′), 5.96 (1H, br s, -CONH-), 4.91, 4.90
(2H, br s, H-29), 4.48 (1H, m, -NHCH-), 3.91 (2H, s, H2-30), 3.60 (2H, t, J = 7.0 Hz, 30-
OCH2CH2Ph(p-Br)), 3.17 (1H, dd, J = 11.0, 5.6 Hz, H-3), 2.89 (1H, t, J = 7.5 Hz, H-19), 2.39
(1H, m, 30-OCH2CH2Ph(p-Br)), 0.96 (12H, s, leucine moiety -(CH3)2, 2 × CH3), 0.82, 0.79, 0.75
(3H each, s, 3 × CH3), MS m/z 766.38 (M− - 1); Compound 21: 1H NMR (300 MHz, CDCl3): δ
7.18-6.87 (4H, m, Ar-H-2′, 3′), 5.96 (1H, br s, -CONH-), 4.91, 4.90 (2H, br s, H-29), 4.48 (1H, m,
-NHCH-), 3.91 (2H, s, H2-30), 3.62 (2H, t, J = 6.8 Hz, 30-OCH2CH2Ph(p-Cl)), 3.17 (1H, dd, J =
11.0, 5.6 Hz, H-3), 2.87 (1H, t, J = 7.5 Hz, H-19), 2.36-2.06 (3H, m, 30-OCH2CH2Ph(p-Cl),
H-13), 0.96 (15H, s, leucine moiety -(CH3)2, 3 × CH3), 0.81, 0.76 (3H each, s, 2 × CH3), MS m/z
722.40 (M− - 1); Compound 22: 1H NMR (300 MHz, CDCl3): δ 5.61 (1H, d, J = 8 Hz, -CONH-),
4.92, 4.90 (H each, s, H-29), 4.59 (1H, m, -NHCH-), 3.94 (2H, s, H2-30), 3.72 (4H, m, -
N(CH2CH2)2O), 3.58 (2H, t, J = 5.7 Hz, 30-OCH2CH2-morpholine), 3.18 (1H, dd, J = 11.4, 4.6
Hz, H-3), 3.01 (1H, m, H-19), 2.60 (2H, t, J = 5.4 Hz, 30-OCH2CH2-morpholine), 2.53 (4H, m, -
N(CH2CH2)2O), 1.00 (6H, s, leucine moiety -(CH3)2), 0.96 (6H, s, 2 × CH3), 0.89, 0.85, 0.80 (3H
each, s, 3 × CH3), MS m/z 697.40 (M− - 1).
23. 20S proteasome assay: 20S proteasome assay kits were purchased from Calbiochem, San Diego,
CA. Measurement of the hydrolysis of the fluorogenic substrate Suc-Leu-Leu-Val-Tyr-AMC in
the presence of the proteasome activator PA28 (16 µg/mL) is used to detect the chymotrypsin-like
activity of the human 20S proteasome. Fluorescence generated from the proteolytic reaction in the
presence of various concentrations of BA derivatives was measured using a BioTek fluorometer
(Winooski, Vermont). The 50% inhibitory concentration (IC50) is defined as the inhibitor
concentration that reduces the reaction rate by 50%. The velocity of reaction (ΔRFU(360/460)/
min) was plotted against the log-concentration of the inhibitor to determine the IC50.
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Structures of BA (1) and its derivatives (2, 23, 24).
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Reactions and conditions: (a) acid chloride, Et3N, CH2Cl2, rt; (b) acid, EDCI, DMAP, Et3N,
CH2Cl2, rt; (c) acid anhydride, DMAP, pyridine, reflux.
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Reactions and conditions: (a) Ac2O, pyridine, 78°C, 4h; (b) (CO2)Cl2, leucine methyl ester,
Et3N, CH2Cl2, rt; (c) NBS, acetonitrile, rt; (d) 2N NaOH, MeOH/THF, rt; (e) step 1:
nucleophilic compounds, NaH, THF; step 2: MeOH-H2O.
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Table 1
The inhibition on the chymotrypsin-like activity of 20S proteasome of 3–24 with 2, LLM-F, and lactacystin as
controls.
Compound IC50 (µM) a Compound IC50 (µM) a
3 > 40 16 3.67
4 > 40 17 2.47
5 10.91 18 3.34
6 11.06 19 2.40
7 > 40 20 1.56
8 7.99 21 1.80
9 > 40 22 3.13
10 7.05 23 > 40
11 2.96 24 > 40
12 > 40 2 9.20
13 1.42 LLM-F 5.25
14 5.85 lactacystin 5.60
15 13.21
a
The IC50 values in the table are the averages from three experiments.
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